INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
St Bartholomew's Hospital
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de St Bartholomew's Hospital (9)
2023
-
Importance of personal development for a diverse workforce in thoracic surgery: The art of Curriculum Vitae building and interviewing
Interdisciplinary cardiovascular and thoracic surgery
2021
-
Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection
BJS Open
-
Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score
British Journal of Surgery, Vol. 19, Núm. 4
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477
2009
-
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline
British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903
2008
-
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
British Journal of Haematology, Vol. 143, Núm. 2, pp. 222-229
2007
-
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial
Blood, Vol. 110, Núm. 10, pp. 3557-3560
-
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
British Journal of Haematology, Vol. 137, Núm. 5, pp. 429-435
2005
-
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
New England Journal of Medicine, Vol. 352, Núm. 24, pp. 2487-2498